Want to see ANNX full AI Analyst Report?
ANNX Stock Chart & Stats
$6.54
-$0.26(-5.25%)
At close: 4:00 PM EST
$6.54
-$0.26(-5.25%)
Day’s Range― - ―
52-Week Range$1.85 - $7.18
Previous CloseN/A
Volume252.73K
Average Volume (3M)2.72M
Market Cap
$802.83M
Enterprise Value$441.03M
Total Cash (Recent Filing)$225.03M
Total Debt (Recent Filing)$25.43M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Aug 17, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.22
Shares Outstanding163,842,540
10 Day Avg. Volume3,079,616
30 Day Avg. Volume2,716,651
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)3.68
Price to Sales (P/S)0.00
P/FCF Ratio-4.18
Enterprise Value/Market Cap0.55
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-231.87
Enterprise Value/Ebitda-2.28
Forecast
1Y Price Target
$10.00Price Target Upside52.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.95
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
C1q-targeted Clinical-stage PipelineAnnexon’s focused scientific strategy—antibody candidates that inhibit C1q and the classical complement cascade—creates a clear, durable R&D thesis. Having lead programs (ANX005, ANX007) in clinical evaluation reduces early-stage science risk versus preclinical portfolios and supports program-specific commercialization optionality over months.
Supportive Balance Sheet & Low LeverageA relatively sizable equity cushion and low debt-to-equity (~0.12) provide structural financial flexibility for a clinical-stage biotech. This lowers immediate solvency risk and supports continued funding of clinical programs or partner negotiations over the medium term, even as cash is consumed.
Capital-raising Flexibility And Governance ContinuityShareholder approval to increase authorized shares materially expands the company’s structural ability to raise capital without further charter amendments. Coupled with auditor ratification and director elections, this indicates governance continuity and practical flexibility to execute financing or partnership transactions when needed.
Bears Say
Pre-revenue With Large Recurring LossesAnnexon remains pre-revenue and recorded a substantial TTM net loss (~$196M). Persistent large losses without product revenues mean the firm must rely on external funding or partnerships to sustain operations, a structural constraint that affects long-term viability absent clinical or commercial inflection points.
Accelerating Cash Burn / Weak Cash GenerationOperating and free cash flow are deeply negative (TTM ~ -$183M) and worsened materially versus 2024. Accelerating cash burn shortens runway, raises the probability of near-term financing needs, and increases dilution risk—structural pressures on strategy and capital allocation over the coming months.
Increased Authorized Shares Heightens Dilution RiskWhile the charter change enables financing flexibility, increasing authorized shares by two-thirds structurally raises the potential for equity dilution. Given ongoing heavy losses and cash burn, the amendment increases the likelihood that future capital will be raised through equity issuance, diluting existing holders over time.
Annexon Biosciences News
ANNX FAQ
What was Annexon Biosciences, Inc.’s price range in the past 12 months?
Annexon Biosciences, Inc. lowest stock price was $1.85 and its highest was $7.18 in the past 12 months.
What is Annexon Biosciences, Inc.’s market cap?
Annexon Biosciences, Inc.’s market cap is $802.83M.
When is Annexon Biosciences, Inc.’s upcoming earnings report date?
Annexon Biosciences, Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 46 days.
How were Annexon Biosciences, Inc.’s earnings last quarter?
Annexon Biosciences, Inc. released its earnings results on May 07, 2026. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.283 by $0.053.
Is Annexon Biosciences, Inc. overvalued?
According to Wall Street analysts Annexon Biosciences, Inc.’s price is currently Undervalued.
Does Annexon Biosciences, Inc. pay dividends?
Annexon Biosciences, Inc. does not currently pay dividends.
What is Annexon Biosciences, Inc.’s EPS estimate?
Annexon Biosciences, Inc.’s EPS estimate is -0.24.
How many shares outstanding does Annexon Biosciences, Inc. have?
Annexon Biosciences, Inc. has 163,842,540 shares outstanding.
What happened to Annexon Biosciences, Inc.’s price movement after its last earnings report?
Annexon Biosciences, Inc. reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.283. Following the earnings report the stock price went up 3.08%.
Which hedge fund is a major shareholder of Annexon Biosciences, Inc.?
Currently, no hedge funds are holding shares in ANNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Annexon Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (52.91% Upside)
$10.00 (52.91% Upside)
Blogger Sentiment
Bullish
ANNX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
137.91%
12-Months-Change
Fundamentals
Return on Equity
-101.19%
Trailing 12-Months
Asset Growth
-13.25%
Trailing 12-Months
Company Description
Annexon Biosciences, Inc.
Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in antibody-mediated autoimmune disorders and complement-driven neurodegeneration. The company's developmental pipeline features several promising candidates. ANX005, a monoclonal antibody, is in advanced clinical testing, undergoing Phase II/III trials for Guillain-Barré syndrome, as well as Phase II trials for warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis. Another candidate, ANX009, is currently in Phase Ib studies for lupus nephritis. Additionally, ANX007 is progressing through Phase II clinical trials for the treatment of geographic atrophy, an eye disease. Further investigational assets include ANX105, a monoclonal antibody being developed for neurodegenerative indications, and ANX1502, an oral small molecule under investigation for specific autoimmune conditions. Annexon, Inc. was established in 2011 and operates from its headquarters in Brisbane, California.
ANNX Stock 12 Month Forecast
Average Price Target
$10.00
▲(52.91% Upside)
Technical Analysis
Galectin Therapeutics
―
Aldeyra Therapeutics
―
Editas Medicine
―
Alector
―
Neumora Therapeutics, Inc.
―
Ownership Overview
7.11% Insiders
18.73% Mutual Funds
42.32% Other Institutional Investors
16.33% Public Companies and
Individual Investors